Clinical Trials Sponsored by Genesis Pharma S.A.

Total 289 results

NewLink Genetics Corporation

Completed

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers (NLG2111)

Healthy

United States
NewLink Genetics Corporation

Completed

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Cancer | Solid Tumor

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
Faes Farma, S.A.

Not yet recruiting

Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.

Colitis, Ulcerative
Faes Farma, S.A.

Completed

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

Urticaria

Argentina, Belgium, France, Germany, Poland, Romania, Spain
Faes Farma, S.A.

Completed

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

Healthy

United States
Faes Farma, S.A.

Completed

Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency (WORFEROL)

Vitamin D Deficiency | Vitamin D Insufficiency

Spain, France, Bulgaria, Czechia, Italy, Serbia, Slovakia
Faes Farma, S.A.

Completed

Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis
NewLink Genetics Corporation

Terminated

Immunotherapy Study for Patients With Stage IV Melanoma

Metastatic Melanoma | Stage IV Melanoma

United States
NewLink Genetics Corporation

Terminated

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)

Melanoma

United States
NewLink Genetics Corporation

Completed

Immunotherapy Study for Metastatic Renal Cell Cancer

Metastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal Cancer

United States
NewLink Genetics Corporation

Completed

NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Solid Tumor

United States
NewLink Genetics Corporation

Completed

A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
NewLink Genetics Corporation

Completed

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Russian Federation, Ukraine
NewLink Genetics Corporation

Completed

Vaccine Treatment for Advanced Malignant Melanoma

Malignant Melanoma

United States
NewLink Genetics Corporation

Completed

Vaccine Treatment for Hormone Refractory Prostate Cancer

Prostate Cancer

United States
NewLink Genetics Corporation

Completed

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Metastatic Renal Cell Carcinoma

Korea, Republic of, United States
NewLink Genetics Corporation

Terminated

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Malignant Brain Tumor

United States
NewLink Genetics Corporation

Terminated

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
NewLink Genetics Corporation

Withdrawn

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Cancer | Ovarian Cancer | Solid Tumor

United States
NewLink Genetics Corporation

Terminated

Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor Malignancy

United States
NewLink Genetics Corporation

Completed

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Ependymoma | Medulloblastoma | Diffuse Intrinsic Pontine Glioma | Malignant Brain Tumor | Primary CNS Tumor

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Solid Tumors

United States
NewLink Genetics Corporation

Completed

Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
NewLink Genetics Corporation

Completed

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Completed

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Poland
NewLink Genetics Corporation

Terminated

Vaccine Treatment for Advanced Breast Cancer

Breast Cancer

United States
Faes Farma, S.A.

Completed

Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)

Chronic Urticaria | Allergic Rhinoconjunctivitis

Australia, Germany, Sweden
Faes Farma, S.A.

Completed

Oral Bioavailability of Bilastine (BIOBI)

Healthy

Spain
Faes Farma, S.A.

Completed

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

Perennial Allergic Rhinitis
Faes Farma, S.A.

Completed

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

Seasonal Allergic Rhinitis
Faes Farma, S.A.

Completed

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber

Seasonal Allergic Rhinitis

Austria
Redwood Pharma AB
Cross Research S.A.

Completed

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Dry Eye Syndromes

Austria, Germany, Hungary
Avizorex Pharma, S.L.

Unknown

Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome (AVX012CT001)

Dry Eye Syndrome

Spain
Abivax S.A.
Orion Corporation, Orion Pharma

Active, not recruiting

Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

Ulcerative Colitis

Belgium
Johns Hopkins University
Addex Pharma S.A.

Completed

PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration

Healthy

United States
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
PT. Innovative Pharma Solutions
Archivel Farma S.L.; RUTI Immunotherapeutics S.L.

Withdrawn

A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19)

COVID-19
Grupo Español Multidisciplinar de Melanoma
Roche Farma, S.A; Pivotal S.L.

Completed

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

Spain
Tedec-Meiji Farma, S.A.

Completed

Efficacy and Safety of 3 Different Dosage Regimens of Hyaluronic Acid in Patients With Knee Osteoarthritis (OA)

Osteoarthritis of the Knee

Spain
Tedec-Meiji Farma, S.A.

Completed

Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee

Osteoarthritis of the Knee
Tedec-Meiji Farma, S.A.

Completed

Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis

Urinary Tract Infections

Spain, Greece
Tedec-Meiji Farma, S.A.

Completed

Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis

Knee Osteoarthritis

Spain
Medical University of Warsaw
Adamed Pharma S.A.

Not yet recruiting

L Rhamnosus ATCC 53103 & L Reuteri DSM 29063 Compared With L Rhamnosus ATCC 53103 for Preventing AAD in Children (FLOSTRUM)

Antibiotic-associated Diarrhea

Poland
Neuropore Therapies Inc.
UCB S.A. - Pharma Sector

Completed

Phase 1 Study of NPT200-11 in Healthy Subjects

Healthy Volunteers

United States
Mesoestetic Pharma Group S.L.

Completed

Efficacy and Performance Evaluation of mIntense L+AS 25 mg/ml Hyaluronic Acid for the Correction of Moderate to Deep Wrinkles and Folds (M-INT-LS)

Skin Aging | Skin Wrinkling

Bulgaria

3

Subscribe